Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Small Molecules Studied
Download: Excel (XLSX), Comma-separated (CSV), Images (Zip file)
| HMS LINCS ID | Name | Alternative Names | LINCS ID | Structure Image | PubChem CID |
|---|---|---|---|---|---|
| 10008-3 | Sorafenib | BAY-439006 | LSM-1008 |  | 216239 |
| 10013-3 | GSK461364 | GSK461364A | LSM-1013 |  | 15983966 |
| 10014-3 | GW843682X | GW843682 | LSM-1014 |  | 9826308 |
| 10021-5 | Tozasertib | VX680; MK-0457 | LSM-1021 |  | 5494449 |
| 10023-3 | Imatinib | Gleevec; Glivec; CGP-57148B; STI-571 | LSM-1023 |  | 5291 |
| 10026-3 | PD173074 | LSM-1026 |  | 1401 | |
| 10029-2 | GW-5074 | LSM-1029 |  | 5034 | |
| 10035-2 | Sigma A6730 | KIN001-102; AKT inhibitor VIII; Akt1/2 kinase inhibitor | LSM-1035 |  | 10196499 |
| 10048-7 | PD184352 | CI-1040 | LSM-1048 |  | 6918454 |
| 10048-6 | PD184352 | CI-1040 | LSM-1048 |  | 6918454 |
| 10051-3 | Lapatinib | GW-572016; Tykerb | LSM-1051 |  | 208908 |
| 10052-3 | Sirolimus | Rapamycin | LSM-1052 |  | 5040 |
| 10056-2 | Selumetinib | AZD6244; Array142886 | LSM-1056 |  | 10127622 |
| 10062-3 | GSK1070916 | KIN001-216 | LSM-1062 |  | 46885626 |
| 10096-2 | ZM-447439 | LSM-1096 |  | 9914412 | |
| 10097-3 | Erlotinib | OSI-774 | LSM-1097 |  | 176870 |
| 10098-2 | Gefitinib | ZD1839; Iressa | LSM-1098 |  | 123631 |
| 10099-2 | Nilotinib | AMN-107 | LSM-1099 |  | 644241 |
| 10102-3 | Taxol | Paclitaxel | LSM-1102 |  | 441276 |
| 10107-5 | MG-132 | LSM-1107 |  | 462382 | |
| 10107-2 | MG-132 | LSM-1107 |  | 462382 | |
| 10108-2 | Geldanamycin | LSM-42789 |  | 644250 | |
| 10110-3 | FR180204 | FR 180204; KIN001-230 | LSM-42790 |  | 11493598 |
| 10133-2 | Afatinib | BIBW-2992 | LSM-43226 |  | 57519523 |
| 10136-2 | TPCA-1 | LSM-1136 |  | 9903786 |